Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation

Развитие нанотехнологий для улучшения таргетной терапии рака: преодоление препятствий клической имплементации
Manimaran Vasanthan, Mohammad Chehelgerdi, Natrayan Lakshmaiya, Omer Qutaiba B. Allela, Ali H. Amin, Reza Akhavan‐Sigari, Patrik Viktor, Matin Chehelgerdi, Renzon Daniel Cosme Pecho, J. Narayanan, Devendra Pratap Rao, Tamilanban Thamaraikani, Mohamed J. Saadh, Ayesha Amajd, Mabrouk A. Abo‐Zaid, Roxana Yolanda Castillo-Acobo, Ahmed Ismail
2023-10-09

clinical translation hurdlesmaterials sciencenanocarriersnanotechnology for cancer targetingprotein engineering
The use of nanotechnology has the potential to revolutionize the detection and treatment of cancer. Developments in protein engineering and materials science have led to the emergence of new nanoscale targeting techniques, which offer renewed hope for cancer patients. While several nanocarriers for medicinal purposes have been approved for human trials, only a few have been authorized for clinical use in targeting cancer cells. In this review, we analyze some of the authorized formulations and discuss the challenges of translating findings from the lab to the clinic. This study highlights the various nanocarriers and compounds that can be used for selective tumor targeting and the inherent difficulties in cancer therapy. Nanotechnology provides a promising platform for improving cancer detection and treatment in the future, but further research is needed to overcome the current limitations in clinical translation.
1
Further research is required to overcome current limitations before nanotechnology can be broadly implemented in clinical cancer detection and treatment.
2
Nanotechnology has strong potential to revolutionize cancer detection and treatment through nanoscale targeting techniques developed via protein engineering and materials science.
3
Several nanocarriers have progressed to human trials, but only a few have been authorized for clinical use specifically for targeting cancer cells.
4
The review analyzes authorized nanocarrier formulations and identifies significant challenges in translating laboratory nanotechnology results to clinical practice.
5
Various nanocarriers and compounds exist for selective tumor targeting, but inherent difficulties in cancer therapy limit their current clinical translation.

Nanotechnology-based nanocarriers and nanoscale targeting formulations for selective tumor targeting in cancer treatment

Challenges and limitations in clinical translation and implementation of nanoscale targeting techniques and authorized nanocarrier formulations for selective cancer detection and therapy

Publication Details
Publication Date
2023-10-09
Journal
Publisher
ISSN
Cited by
1053
Access Type
Author Information
Authors
Manimaran Vasanthan
Mohammad Chehelgerdi
Natrayan Lakshmaiya
Omer Qutaiba B. Allela
Ali H. Amin
Reza Akhavan‐Sigari
Patrik Viktor
Matin Chehelgerdi
Renzon Daniel Cosme Pecho
J. Narayanan
Devendra Pratap Rao
Tamilanban Thamaraikani
Mohamed J. Saadh
Ayesha Amajd
Mabrouk A. Abo‐Zaid
Roxana Yolanda Castillo-Acobo
Ahmed Ismail
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%